On July 2, Sanofi rose 3.19% in regular trading, trading at $42.98/share, with turnover of $25.48 million. The stock rebounded sharply after earlier session weakness triggered by an EU antitrust investigation announcement.

The rebound was driven by two key catalysts. First, the broader pharmaceutical sector rallied strongly, with AstraZeneca up 4.81%, Novo Nordisk up 3.57%, and Eli Lilly up 2.45%, lifting overall sector sentiment and attracting capital inflows. Second, Sanofi reported positive pipeline developments as its rare disease drug Nexviazyme met the primary endpoint in a Phase 3 clinical trial targeting infantile-onset Pompe disease in patients aged six months and younger who were previously untreated. The company plans to file for US regulatory approval to expand the drug's eligible patient population.

The EU antitrust probe announced on June 26, which alleges Sanofi disparaged competitor CSL Seqirus' flu vaccine Fluad through misleading communications to promote its own Efluelda vaccine, had pressured the stock earlier in the session. However, strong sector momentum and the clinical milestone enabled a full intraday recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)